Sec Form 3 Filing - Conway Vikki L @ TEVA PHARMACEUTICAL INDUSTRIES LTD - 2023-09-25

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Conway Vikki L 2. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See "Remarks" (Last) (First) (Middle) C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET 3. Date of Earliest Transaction (MM/DD/YY) 09/25/2023 (Street) TEL AVIV, L3 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 48.76 ( 1 ) 03/12/2024 Ordinary Shares ( 2 ) 2,268 D Stock Options (right to buy) $ 60.21 ( 3 ) 03/12/2025 Ordinary Shares ( 2 ) 3,504 D Stock Options (right to buy) $ 53.5 ( 4 ) 03/17/2026 Ordinary Shares ( 2 ) 8,003 D Stock Options (right to buy) $ 34.7 ( 5 ) 03/03/2027 Ordinary Shares ( 2 ) 15,003 D Stock Options (right to buy) $ 16.99 ( 6 ) 09/18/2027 Ordinary Shares ( 2 ) 4,571 D Stock Options (right to buy) $ 19.16 ( 7 ) 03/02/2028 Ordinary Shares ( 2 ) 25,003 D Restricted Share Units ( 9 ) ( 8 ) ( 8 ) Ordinary Shares ( 2 ) 4,294 D Restricted Share Units ( 9 ) ( 10 ) ( 10 ) Ordinary Shares ( 2 ) 9,911 D Restricted Share Units ( 9 ) ( 11 ) ( 11 ) Ordinary Shares ( 2 ) 21,354 D Restricted Share Units ( 9 ) ( 12 ) ( 12 ) Ordinary Shares ( 2 ) 20,717 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Conway Vikki L C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A STREET TEL AVIV, L3 See "Remarks" Signatures /s/ Dov Bergwerk, as attorney-in-fact for Vikki L. Conway 10/05/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Stock options were granted on March 12, 2014, with 1,134 having vested on each of March 12, 2016 and March 12, 2017. ( 2 )The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. ( 3 )Stock options were granted on March 12, 2015, with 876 having vested on each of March 12, 2016, March 12, 2017, March 12, 2018, and March 12, 2019. ( 4 )Stock options were granted on March 17, 2016, with 2,000 having vested on each of March 17, 2017, March 17, 2018 and March 12, 2019, and 2,003 having vested on March 17, 2020. ( 5 )Stock options were granted on March 3, 2017, with 3,750 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 3,753 having vested on March 3, 2021. ( 6 )Stock options were granted on September 18, 2017, with 4,571 having vested on September 18, 2019. ( 7 )Stock options were granted on March 2, 2018, with 6,250 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021, and 6,253 having vested on March 2, 2022. ( 8 )Restricted share units were granted on February 28, 2020, with 4,294 vesting on February 28, 2024. ( 9 )Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share. ( 10 )Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025. ( 11 )Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026. ( 12 )Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.

Remarks: Exhibit 24 - Power of Attorney.Acting Head of Global Human Resources.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.